Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared…
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared…
Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment o…
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today completed its change of legal form to a Socie…
The Waldburg-Zeil Klinik Bad Wurzach now offers the "gold standard" in gait rehabilitation. This is how the Head of Neur…
Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan to…
Peter Kopf founded medica Medizintechnik GmbH 33 years ago and led the company's fortunes as CEO ever since. Together wi…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for maj…
In the constantly evolving world of rehabilitation technology, THERA-Trainer, a family-run company with over 35 years of…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated gl…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializin…